Oncobiologics (OTLK) Competitors $1.04 -0.05 (-4.59%) Closing price 04:00 PM EasternExtended Trading$1.06 +0.02 (+1.83%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. CLYM, NKTX, THTX, SLN, CLLS, CRDF, FBRX, HURA, CHRS, and BHSTShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Climb Bio (CLYM), Nkarta (NKTX), Theratechnologies (THTX), Silence Therapeutics (SLN), Cellectis (CLLS), Cardiff Oncology (CRDF), Forte Biosciences (FBRX), TuHURA Biosciences (HURA), Coherus Oncology (CHRS), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors Climb Bio Nkarta Theratechnologies Silence Therapeutics Cellectis Cardiff Oncology Forte Biosciences TuHURA Biosciences Coherus Oncology BioHarvest Sciences Oncobiologics (NASDAQ:OTLK) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Do analysts rate OTLK or CLYM? Oncobiologics currently has a consensus price target of $9.60, suggesting a potential upside of 823.08%. Climb Bio has a consensus price target of $9.00, suggesting a potential upside of 300.00%. Given Oncobiologics' higher possible upside, equities research analysts plainly believe Oncobiologics is more favorable than Climb Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Climb Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Which has preferable valuation & earnings, OTLK or CLYM? Climb Bio is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologicsN/AN/A-$75.37M-$0.57-1.82Climb BioN/AN/A-$73.90M-$0.70-3.21 Does the media refer more to OTLK or CLYM? In the previous week, Oncobiologics and Oncobiologics both had 2 articles in the media. Climb Bio's average media sentiment score of 1.57 beat Oncobiologics' score of 0.45 indicating that Climb Bio is being referred to more favorably in the news media. Company Overall Sentiment Oncobiologics Neutral Climb Bio Very Positive Which has more volatility & risk, OTLK or CLYM? Oncobiologics has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Do insiders and institutionals believe in OTLK or CLYM? 11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 4.8% of Oncobiologics shares are held by insiders. Comparatively, 0.8% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is OTLK or CLYM more profitable? Oncobiologics' return on equity of 0.00% beat Climb Bio's return on equity.Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -332.30% Climb Bio N/A -23.10%-22.47% SummaryClimb Bio beats Oncobiologics on 7 of the 13 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.20M$3.13B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.60%P/E Ratio-1.8221.3074.5925.92Price / SalesN/A257.21453.5485.33Price / CashN/A45.3337.0859.91Price / Book-0.349.6112.156.29Net Income-$75.37M-$53.29M$3.28B$270.77M7 Day Performance11.23%0.28%0.99%3.36%1 Month Performance-50.24%8.91%7.21%6.41%1 Year Performance-83.98%13.14%63.07%28.24% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.1412 of 5 stars$1.04-4.6%$9.60+823.1%-84.5%$46.20MN/A-1.8220Short Interest ↑High Trading VolumeCLYMClimb Bio3.7204 of 5 stars$2.23-3.0%$9.00+303.6%N/A$151.11MN/A-3.199NKTXNkarta2.3429 of 5 stars$2.12-3.6%$13.60+541.5%-67.8%$150.57MN/A-1.43140Positive NewsTHTXTheratechnologiesN/A$3.24-0.3%N/A+166.7%$148.98M$85.87M-17.05140News CoverageShort Interest ↓SLNSilence Therapeutics2.4181 of 5 stars$4.81-5.7%$33.83+603.4%-73.7%$143.96M$27.17M-2.92100CLLSCellectis3.3865 of 5 stars$2.57-1.2%$4.00+55.6%+31.3%$142.84M$49.22M-3.13290Positive NewsShort Interest ↓Gap UpCRDFCardiff Oncology2.7073 of 5 stars$2.10+1.0%$10.10+381.0%-10.0%$139.71M$545K-2.4120News CoveragePositive NewsFBRXForte Biosciences3.3694 of 5 stars$11.00-2.0%$68.00+518.2%+47.5%$136.76MN/A-0.685News CoveragePositive NewsShort Interest ↓High Trading VolumeHURATuHURA Biosciences1.8903 of 5 stars$2.70-3.9%$12.67+369.1%N/A$135.14MN/A0.00N/ACHRSCoherus Oncology4.1671 of 5 stars$1.16-1.7%$4.68+303.7%+0.0%$134.83M$266.96M0.75330BHSTBioHarvest Sciences2.4345 of 5 stars$8.18+2.8%$13.67+67.1%N/A$134.32M$25.19M-11.69N/AGap Up Related Companies and Tools Related Companies Climb Bio Competitors Nkarta Competitors Theratechnologies Competitors Silence Therapeutics Competitors Cellectis Competitors Cardiff Oncology Competitors Forte Biosciences Competitors TuHURA Biosciences Competitors Coherus Oncology Competitors BioHarvest Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
